Authenticx Announces AI Solution Revolutionizing Adverse Event Reporting
Latest product for detecting healthcare-specific compliance events and streamlining reporting INDIANAPOLIS, Aug. 13, 2024 /PRNewswire/ -- Authenticx, the new standard in...
Latest product for detecting healthcare-specific compliance events and streamlining reporting INDIANAPOLIS, Aug. 13, 2024 /PRNewswire/ -- Authenticx, the new standard in...
This financing is expected to support 2024 filing of New Drug Applications forNRX-100 (ketamine) and NRX-101 and to support launch...
AbbVie, Astellas, Eikon, Merck, Moderna, Roche, and more share new ideas to advance drug development PLEASANTON, Calif., Aug. 13, 2024...
NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Inc. magazine revealed today that Acclinate has ranked No. 539 on its 2024...
Leapcure enhances clinical trials and affordable patient recruitment with strategic acquisition of Honeybee Trials.REDWOOD CITY, CA / ACCESSWIRE / August...
0% Markup on Generics, Best Prices for Brand and OTC MedicationsNEWARK, CA / ACCESSWIRE / August 13, 2024 / CostPill,...
RADIAN's Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on...
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net...
For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC / ACCESSWIRE / August...
ROSCREA, Ireland and FREIBURG, Germany, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed...
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™...
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone...
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of...
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase...
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10...
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that...
LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is...
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded...
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial...